Invasive aspergillosis in an immunocompromised patient: Clinical and therapeutic considerations;Aspergillosi invasiva in paziente immunocompromesso: Considerazioni cliniche e terapeutiche

Infezioni in Medicina

Volumn 15, Issue 4, 2007, Pages 262-266

  De Rosa, Francesco Giuseppe ^a   Garazzino, Silvia ^a   Audagnotto, Sabrina ^a   Michelazzo, Marianna ^a   Gobbi, Federico ^a   Di Perri, Giovanni ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Invasive aspergillosis; Long term treatment; Voriconazole

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; LINEZOLID; STEROID; VANCOMYCIN; VORICONAZOLE;

ADULT; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; AUTOIMMUNE THROMBOCYTOPENIA; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; CHLAMYDOPHILA PNEUMONIAE; HOST SUSCEPTIBILITY; HUMAN; HUMAN TISSUE; IMMUNOCOMPROMISED PATIENT; LEGIONELLA; LUNG LAVAGE; MYCOBACTERIUM TUBERCULOSIS; MYCOPLASMA PNEUMONIAE; POLYMERASE CHAIN REACTION; TRANSBRONCHIAL BIOPSY;

ADULT; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; BRONCHIAL FISTULA; ENCEPHALITIS; FEMALE; FUNGEMIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, FUNGAL; NEUROASPERGILLOSIS; PLEURAL DISEASES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RESPIRATORY TRACT FISTULA; STENOTROPHOMONAS MALTOPHILIA;

EID: 38849189358     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Lin S.J., Schranz J., Teutsch S.M. Aspergillosis case-fatality rate: systematic review of the literature. Clin. Infect. Dis. 32, 358-356, 2001.
2. Patterson T.F., Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. Aspergillus Study Group. Medicine (Baltimore), 79, 250-260, 2000.
3. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med., 347, 408-415, 2002.
4. Steinbach W.J., Stevens D.A. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin. Infect. Dis. 37 Suppl 3, S157-187, 2003.
5. Pfaller M.A., Messer S.A., Hollis R.J., Jones R.N. SENTRY Participants Group. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob. Agents Chemother. 46, 1032-1037, 2002.
6. Espinel-Ingroff A., Boyle K., Sheehan D.J. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 150, 101-115, 2001.
7. Stevens D.A., Moss R.B., Kurup V.P. et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin. Infect. Dis. 37 Suppl. 3, S225-264, 2003.
8. Kan V.L., Bennett J.E. Lectin-like attachment sites on murine pulmonary alveolar macrophages bind Aspergillus fumigatus conidia. J. Infect. Dis. 158, 407-414, 1988.
9. Schaffner A. Therapeutic concentrations of glucocorticoids suppress the antimicrobial activity of human macrophages without impairing their responsiveness to gamma interferon. J. Clin. Invest. 76, 1755-1764, 1985.